The financing validates investor confidence in Helex’s novel LNP‑AI approach and provides the resources needed to accelerate drug candidates for high‑unmet‑need kidney disorders, positioning the company for future partnerships or acquisition in the biotech sector.
Helex, a therapeutics firm focused on genetic kidney diseases, announced an oversubscribed $3.5 million seed round led by pi Ventures with participation from Bluehill Capital, SOSV and a global syndicate of investors. The funding brings Helex's total capital raised to over $6 million, supporting its AI‑driven drug design and LNP delivery platforms.
Comments
Want to join the conversation?
Loading comments...